| Sign In to gain access to subscriptions and/or personal tools. |
Quantitative Cell-Based High-Content Screening for Vasopressin Receptor Agonists Using Transfluor® Technology
1 Cellomics, Inc., Pittsburgh, PA.
* To whom correspondence should be addressed. E-mail: rghosh{at}cellomics.com.
The authors demonstrate the use of a simple, universal G-protein-coupled receptor (GPCR) assay to screen for agonists for a specific GPCR. Cells stably expressing a green fluorescent protein (GFP)--labeled Key Words:
high-content screening, cell-based assays, vasopressin,
First published on August 29, 2005, doi:10.1177/1087057105274896 This article has been cited by other articles:
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
-arrestin fusion protein and the vasopressin V2 receptor (V2R) were used in a high-content screening (HCS) assay to screen a small peptide library for V2R agonists. Cells were treated with the peptides at a final concentration of 500 nM for 30 min. Agonist stimulation causes V2R internalization into endosomes. GFP-
